Skip to main content

claseprubart

claseprubart: developed by 1 company · 4 clinical trials tracked.

claseprubart evidence translation

What we can confirm

What it means

Source-backed records connect claseprubart to DNTH; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could claseprubart → DNTH affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 0 study sponsors

Related indications

Chronic Inflammatory Demyelinating Polyneuropathy; Multifocal Motor Neuropathy; Myasthenia Gravis, GeneralizedChronic Inflammatory Demyelinating PolyneuropathyMyasthenia Gravis, Generalized

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (1)
CompanyPhase
Dianthus Therapeutics, Inc. /DE/ (DNTH)
Chronic Inflammatory Demyelinating Polyneuropathy; Multifoca…
Phase 2
Clinical Trials (4)

A Phase 3 Global, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy, Safety, and Tolerability of Claseprubart (DNTH103) in Patients With Generalized Myasthenia Gravis (EMERGE)

NCT07647510·Phase 3·DNTH
Recruiting

Primary endpoint: Change from Baseline to Week 17 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale Score

InterventionalRandomizedquadruple195 targetStarted 2026-06Completion 2031-093 sites · United StatesDianthus Therapeutics

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of DNTH103 In Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

NCT06858579·Phase 3·DNTH
Recruiting

Primary endpoint: Part B: Time From First Dose to Relapse as Assessed by the Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT)

InterventionalRandomizedtriple256 targetStarted 2025-02Completion 2030-1250 sites · Argentina, Australia, Belgium, Brazil…Dianthus Therapeutics

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults With Multifocal Motor Neuropathy (MOMENTUM)

NCT06537999·Phase 2·DNTH
Active, not recruiting

Primary endpoint: Incidence of Treatment-Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs)

InterventionalRandomizedquadruple46 targetStarted 2024-09Completion 2028-0341 sites · Canada, China, Denmark, France…Dianthus Therapeutics

A Phase 2, Randomized, Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)

NCT06282159·Phase 2·DNTH
Active, not recruiting

Primary endpoint: Incidence of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs)

InterventionalRandomizedquadruple65 enrolledStarted 2024-02Completion 2028-1050 sites · Argentina, Canada, Czechia, Denmark…Dianthus Therapeutics

Frequently asked questions

Who is developing claseprubart?

claseprubart is being developed by Dianthus Therapeutics, Inc. /DE/.

How many clinical trials involve claseprubart?

BioSniper tracks 4 clinical trials involving claseprubart.